Blog
RSS FeedPosted by Michael Wonder on 28 Jun 2020
Obamacare faces unprecedented test as economy sinks
27 June 2020 - The battles over the health law have played out during a decade of continuous economic growth. How ...
Posted by Michael Wonder on 25 Jun 2020
How orphan drug policy could impede access to COVID-19 treatments
25 June 2020 - The Orphan Drug Act of 1983 was passed to promote the development of rare disease treatments. ...
Posted by Michael Wonder on 23 Jun 2020
Pricing remdesivir: a domestic reference price approach
23 June 2020 - As COVID-19 continues to ravage US communities, the costs in terms of lives and lost wages are ...
Posted by Michael Wonder on 22 Jun 2020
Alternative payment models—victims of their own success?
22 June 2020 - The US health care system requires major changes to make health care more affordable and higher quality. ...
Posted by Michael Wonder on 11 Jun 2020
Rare disease therapy development and access remain top FDA priorities during COVID-19
11 June 2020 - The FDA’s work on behalf of people with rare diseases is more important than ever as these ...
Posted by Michael Wonder on 26 May 2020
Medicines New Zealand consulting on a new generation medicines policy
26 May 2020 - The New Zealand Institute of Economic Research have produced a discussion paper for Medicines New Zealand ...
Posted by Michael Wonder on 20 May 2020
Insurers back plan for private health plans to cover kids up to age 30
20 May 2020 - The Morrison government is considering a proposal to allow young Australians to stay on their parents' ...
Posted by Michael Wonder on 16 Apr 2020
A strategy for improving U.S. health care delivery — conducting more randomised, controlled trials
16 April 2020 - Despite the prominence of randomised, controlled trials in medical research, they have rarely been used to evaluate ...
Posted by Michael Wonder on 06 Apr 2020
A coronavirus casualty: delay in comprehensive drug pricing legislation
6 April 2020 - As numbers of new cases of coronavirus mount as well as an increasing death toll, the ...
Posted by Michael Wonder on 30 Mar 2020
Is it worthwhile having private health insurance during the coronavirus epidemic?
31 March 2020 - Major private health funds have delayed scheduled premium hikes and offered fee relief for policyholders who ...
Posted by Michael Wonder on 14 Mar 2020
Insulin costs may be capped in a Medicare program
11 March 2020 - If drug companies and insurers agree to participate, the Trump administration proposes limiting insulin costs to $35 ...
Posted by Michael Wonder on 09 Mar 2020
PhRMA: federal biosimilar payment policies are having a positive effect
4 March 2020 - Katie Verb, director of policy and research for the biopharmaceutical industry group PhRMA, discusses recent policy changes ...
Posted by Michael Wonder on 09 Mar 2020
HHS finalises historic rules to provide patients more control of their health data
9 March 2020 - Final rules require access to health information, spur innovation and aim to end information blocking ...
Posted by Michael Wonder on 08 Mar 2020
Five years on, biosimilars need support from all health care players
6 March 2020 - Today marks a milestone for the U.S. biosimilar market: the FDA approved our first biosimilar, Sandoz’s ...
Posted by Michael Wonder on 08 Mar 2020
Price controls imposed by shortsighted politicians keep new life-saving drugs out
5 March 2020 - Politicians need to step outside the Ottawa bubble and understand how their policies impact the lives of ...